

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUA XIA HEALTHCARE HOLDINGS LIMITED**

**華夏醫療集團有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8143)**

- (I) UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS;  
AND  
(II) RESIGNATION OF EXECUTIVE DIRECTOR, CHAIRMAN  
OF THE BOARD, CHIEF EXECUTIVE OFFICER, AUTHORISED  
REPRESENTATIVE AND CHAIRMAN OF NOMINATION AND  
CORPORATION GOVERNANCE COMMITTEE;  
AND  
(III) APPOINTMENT OF EXECUTIVE DIRECTOR  
AND AUTHORISED REPRESENTATIVE;  
AND  
(IV) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND  
CHAIRMAN OF NOMINATION  
AND CORPORATE GOVERNANCE COMMITTEE;  
AND  
(V) RESUMPTION OF TRADING**

**(I) UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS**

The Board has noticed the increases in the price and trading volume of the Shares today. Having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirms that, save as disclosed below, it is not aware of any reason for such increases in the price and trading volume movements of the Shares or of any information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to be disclosed under Part XIVA of the SFO.

On 17 April 2015, Mr. KL Yung transferred 160,984,141 Shares, represent approximately 9.69% of the entire issued ordinary share capital of the Company as at the date of this announcement, directly owned by him to his indirectly controlled corporation, namely Easeglory. The entire issued share capital of Easeglory is wholly and beneficially owned by Marshal International Limited, which in turn, is wholly and beneficially owned by Mr. KL Yung. As advised by Mr. KL Yung, as part of his personal assets restructuring, he intends to transfer all the remaining Shares directly owned by him to Easeglory.

\* For identification purpose only

**(II) RESIGNATION OF EXECUTIVE DIRECTOR, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE OFFICER, AUTHORISED REPRESENTATIVE AND CHAIRMAN OF NOMINATION AND CORPORATION GOVERNANCE COMMITTEE**

The Board announces that Mr. KL Yung has tendered his resignation as the executive Director, chairman of the Board, chief executive officer, authorised representative and chairman of nomination and corporate governance committee of the Company, all with effect from 20 April 2015 due to the commitment to his personal business. Mr. KL Yung confirmed that he has no disagreement with the Board and that there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

**(III) APPOINTMENT OF EXECUTIVE DIRECTOR AND AUTHORISED REPRESENTATIVE**

The Board announces that Mr. KC Yung has been appointed as an executive Director and authorised representative of the Company with effect from 20 April 2015.

**(IV) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF NOMINATION AND CORPORATE GOVERNANCE COMMITTEE**

The Board further announces that Dr. Jiang Tao has been appointed as chief executive officer and chairman of nomination and corporate governance committee of the Company with effect from 20 April 2015.

**(V) RESUMPTION OF TRADING**

At the request of the Company, trading in the Shares on the Stock Exchange has been halted with effect from 1:00 p.m. on Monday, 20 April 2015 pending the release of this announcement. Application has been made to the Stock Exchange for the resumption of trading of the Shares on the Stock Exchange with effect from 9:00 a.m. on Tuesday, 21 April 2015.

**(I) UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS**

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

The board (the “**Board**”) of directors (the “**Directors**”) of Hua Xia Healthcare Holdings Limited (the “**Company**” together with its subsidiaries, the “**Group**”) has noticed the increases in the price and trading volume of the shares (the “**Shares**”) of the Company today. Having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirms that, save as disclosed below, it is not aware of any reason for such increases in the price and trading volume movements of the Shares or of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

On 17 April 2015, Mr. Yung Kwok Leong (“**Mr. KL Yung**”) transferred 160,984,141 Shares, represent approximately 9.69% of the entire issued ordinary share capital of the Company as at the date of this announcement, directly owned by him to his indirectly controlled corporation, namely Easeglory Holdings Limited (“**Easeglory**”). The entire issued share capital of Easeglory is wholly and beneficially owned by Marshal International Limited, which in turn, is wholly and beneficially owned by Mr. KL Yung. As advised by Mr. KL Yung, as part of his personal assets restructuring, he intends to transfer all the remaining Shares directly owned by him to Easeglory.

## **(II) RESIGNATION OF EXECUTIVE DIRECTOR, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE OFFICER, AUTHORISED REPRESENTATIVE AND CHAIRMAN OF NOMINATION AND CORPORATION GOVERNANCE COMMITTEE**

The Board announces that Mr. KL Yung has tendered his resignation as the executive Director, chairman of the Board, chief executive officer, authorised representative and chairman of nomination and corporate governance committee of the Company, all with effect from 20 April 2015 due to the commitment to his personal business. Mr. KL Yung has confirmed that he has no disagreement with the Board and that there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board wishes to express its appreciation to Mr. KL Yung for his valuable contributions to the Company during his tenure of office.

### **(III) APPOINTMENT OF EXECUTIVE DIRECTOR AND AUTHORISED REPRESENTATIVE**

The Board announces that Mr. KC Yung Ka Chun (“**Mr. KC Yung**”) has been appointed as the executive Director and authorised representative of the Company with effective from 20 April 2015.

Mr. KC Yung, aged 26, obtained his master degree of science in business majoring in accounting from the University of Maryland, College Park in the United States. Mr. KC Yung has entered into a service contract with the Company dated 20 April 2015 for a term of 3 years commencing from the date of the service contract. Mr. KC Yung is entitled to a monthly salary of HK\$50,000 which is determined by the remuneration committee of the Company with reference to his duties and responsibilities with the Company. Mr. KC Yung’s appointment is subject to retirement by rotation and/or re-election at general meeting in accordance with the articles of association of the Company.

Mr. KC Yung is the son of Mr. KL Yung, who is an indirect controlling shareholder of the Company. Mr. KC Yung was appointed as an executive director of Wanjia Group Holdings Limited, a subsidiary of the Company and the issued shares of which were listed on the Main Board of the Stock Exchange, on 10 October 2014 and he resigned as the executive director of Wanjia Group Holdings Limited on 20 April 2015 (both dates inclusive).

As at the date of this announcement, save as disclosed above, Mr. KC Yung did not have any directorships in the last three years in any listed companies the securities of which are listed on any securities market in Hong Kong or overseas or does he hold any other position with the Company and any of its subsidiaries or other major appointments and professional qualifications. Save as disclosed above, Mr. KC Yung does not have any other relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company (within Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on the Growth Enterprise Market (the “**GEM**”) of the Stock Exchange).

As at the date of this announcement, Mr. KC Yung is the holder of 6,600,000 share options of the Company which were granted by the Company on 16 April 2015, Save as disclosed, Mr. KC Yung does not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. KC Yung has confirmed that there are no other matters that need to be brought to the attention of the shareholders of the Company regarding his appointment and there is no other information that needed to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

The Board would like to extend its warmest welcome to Mr. KC Yung for joining the Company.

#### **(IV) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF NOMINATION AND CORPORATE GOVERNANCE COMMITTEE**

The Board further announces that Dr. Jiang Tao has been appointed as chief executive officer and chairman of nomination and corporate governance committee with effect from 20 April 2015.

This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

#### **(V) RESUMPTION OF TRADING**

At the request of the Company, trading in the Shares on the Stock Exchange has been halted with effect from 1:00 p.m. on Monday, 20 April 2015 pending the release of this announcement. Application has been made to the Stock Exchange for the resumption of trading of the Shares on the Stock Exchange with effect from 9:00 a.m. on Tuesday, 21 April 2015.

By order of the Board  
**Hua Xia Healthcare Holdings Limited**  
**Jiang Tao**  
*Executive Director*

Hong Kong, 20 April 2015

*As at the date of this announcement, the executive Directors of the Company are Dr. Jiang Tao, Mr. Zheng Gang, Dr. Huang Jiaqing and Mr. Yung Ka Chun, the non-executive Directors are Dr. Wong Yu Man, James and Mr. Tang Xun, and the independent non-executive Directors are Ms. Wong Ka Wai, Jeanne, Prof. Hu Shanlian and Prof. Lu Chuanzhen.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the GEM website at [www.hkgem.com](http://www.hkgem.com) on the "Latest Company Announcements" page for at least 7 days from the date of its posting and on the website of the Company at [www.huaxia-healthcare.com](http://www.huaxia-healthcare.com)*